ReviewClinicoEconomics and outcomes research : CEOR2026
Cost Burden and Cost-Effectiveness of Rhegmatogenous Retinal Detachment Repair: A Systematic Review of Economic Evaluations.
Review in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To review the economic burden and cost-effectiveness analyses of interventions and management of rhegmatogenous retinal detachment (RRD). Patients and Methods: A comprehensive literature search was conducted on Ovid Medline, Embase and Scopus from inception to March 2025 for articles reporting economic burden, cost analyses, cost-effectiveness, or cost-utility outcomes related to RRD repair. Primary outcomes were the cost of RRD adverse events and repair. Secondary outcomes were the incremental cost-effectiveness ratios (ICER) of RRD repair procedures. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Economic Evaluations. The review protocol was registered in PROSPERO (CRD42023446301). Results: A total of 46 publications met the inclusion criteria and were included in the study. Most studies were conducted in the United States (48%) and adopted payer or provider analytic perspectives. In 23 studies reporting RRD as an adverse event of another condition or intervention, the mean cost of repair was $3,648±2,986, inflated to 2024 US dollars (USD). Across 22 studies assessing cost comparisons of RRD interventions, the cost of the pneumatic retinopexy (PR), pars plana vitrectomy (PPV) and scleral buckle (SB) surgery ranged from $1,093-$4,761, $5,443-$9,903, and $4,411-$8,131, respectively. Considerable heterogeneity existed across economic models, analytic perspectives, willingness-to-pay (WTP) thresholds, and time horizons used in cost-effectiveness studies. Indirect costs, including caregiver burden and productivity loss, were infrequently reported. Conclusion: Although available evidence suggests that RRD is generally associated with favourable cost-effectiveness outcomes, conclusions are limited by methodological heterogeneity, predominance of evidence from high-income settings, and inconsistent reporting of indirect costs. Broader and more standardized economic evaluations, particularly in non-Western settings, are needed to better characterize the global economic impact of RRD repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.